financetom
Business
financetom
/
Business
/
Rumble Fourth-Quarter Loss Widens Despite Revenue Boost
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rumble Fourth-Quarter Loss Widens Despite Revenue Boost
Mar 25, 2025 7:59 AM

10:43 AM EDT, 03/25/2025 (MT Newswires) -- Rumble (RUM) said Tuesday that its fourth-quarter loss widened on a yearly basis even as revenue surged nearly 50%.

The video-sharing platform's per-share loss grew to $1.15 for the December quarter from $0.14 the year before. Two analysts polled by FactSet expected a loss of $0.11. The result reflected a $184.7 million fair value loss related to cryptocurrency firm Tether's $775 million investment in the company.

In December, Tether agreed to purchase about 103.3 million class A shares of Rumble at $7.50 apiece. The investment completed in February.

The company expects the capital raised from the Tether deal to enable further expansion, it said. "As I look ahead, with the Tether transaction now closed, I could not be more excited about the possibilities and the new era we are entering for Rumble," Chief Executive Chris Pavlovski said in an earnings release.

Revenue came in at $30.2 million for the fourth quarter, representing annual growth of 48%. Three analysts surveyed by FactSet estimated $29.7 million.

Rumble logged 68 million average global monthly active users in the fourth quarter, up from 67 million in the prior three-month period. About 52 million of the users were based in the US and Canada, advancing 21% from the third quarter.

For the current quarter, the company expects revenue to rise by at least 25% from the prior-year period. Three analysts' average estimate is $25.1 million.

The firm expects to achieve a breakeven point in terms of adjusted earnings before interest, taxes, depreciation and amortization in 2025. In 2024, adjusted EBITDA was negative $92.1 million, improving from negative $115.3 million in the year before.

Price: 8.10, Change: +0.09, Percent Change: +1.12

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Genmab Says European Commission Grants Marketing Authorization for Tivdak as Cervical Cancer Treatment
Genmab Says European Commission Grants Marketing Authorization for Tivdak as Cervical Cancer Treatment
Mar 31, 2025
12:00 PM EDT, 03/31/2025 (MT Newswires) -- Genmab ( GMAB ) said Monday that the European Commission has granted marketing authorization for Tivdak as a treatment for adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. The company said the approval was based on data from a phase 3 trial that met its...
Update: Largo Drops 9% as It Q4 Loss Narrows; Details Operational Turnaround Plan and Optimization Initiatives
Update: Largo Drops 9% as It Q4 Loss Narrows; Details Operational Turnaround Plan and Optimization Initiatives
Mar 31, 2025
12:00 PM EDT, 03/31/2025 (MT Newswires) -- (Updates shares.) Largo (LGO.TO) late on Friday reported that its fourth-quarter loss narrowed even as revenue fell. The company said it lost US$13 million, or US$0.19 per share, narrowing from a loss of US$13.3 million, or US$13.3 million, in the year-prior quarter Revenue came in at US$24.3 million, down from US$44.2 million. The...
Newsmax Shares Rally in NYSE Debut; Trading Halted on Volatility
Newsmax Shares Rally in NYSE Debut; Trading Halted on Volatility
Mar 31, 2025
11:57 AM EDT, 03/31/2025 (MT Newswires) -- Newsmax ( NMAX ) shares were surging Monday in their debut on the New York Stock Exchange after the company sold 7.5 million Class B shares at $10.00 per share. The shares were up more than 500% at $66.67 in recent trading after opening at $14.00. Trading in the shares was halted at...
BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial
BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial
Mar 31, 2025
12:00 PM EDT, 03/31/2025 (MT Newswires) -- BridgeBio Pharma ( BBIO ) said Monday acoramidis showed statistically significant improvements in clinical outcomes in both variant and wild-type transthyretin amyloid cardiomyopathy, or ATTR-CM, in a phase 3 trial. The study compared acoramidis with placebo for time to all-cause mortality or first cardiovascular-related hospitalization in both variant and wild-type ATTR-CM, the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved